Surajit Dey
Overview
Explore the profile of Surajit Dey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
480
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhattarai P, Lu W, Hardikar A, Gaikwad A, Dey S, Shahzad A, et al.
Clin Sci (Lond)
. 2024 Aug;
138(17):1055-1070.
PMID: 39136529
We previously reported pulmonary arterial remodelling and active endothelial-to-mesenchymal transition (EndMT) in smokers and patients with early chronic obstructive pulmonary disease (COPD). In the present study, we aimed to evaluate...
2.
Dey S, Lu W, Weber H, Chia C, Pathinayake P, Wark P, et al.
ERJ Open Res
. 2024 Jul;
10(4).
PMID: 38978556
https://bit.ly/49DeoFX.
3.
Weldon D, Noureldin M, Richter L, Dey S, Hardinger K, Majerczyk D
Curr Pharm Teach Learn
. 2024 Apr;
16(7):102089.
PMID: 38658215
Graduating student pharmacists who are practice-ready is an essential responsibility of pharmacy programs and heavily emphasized by Accreditation Council of Pharmacy Education (ACPE), pharmacy education's accrediting body. Although several studies...
4.
Shahzad A, Lu W, Dey S, Bhattarai P, Gaikwad A, Jaffar J, et al.
J Clin Med
. 2024 Apr;
13(7).
PMID: 38610892
: Idiopathic pulmonary fibrosis (IPF) is an irreversible lung fibrotic disorder of unknown cause. It has been reported that bacterial and viral co-infections exacerbate disease pathogenesis. These pathogens use adhesion...
5.
Eapen M, Lu W, Dey S, Chia C, Hardikar A, Hassan M, et al.
ERJ Open Res
. 2024 Mar;
10(2).
PMID: 38500797
Background: COPD patients suffer from dysregulated and suppressed immune functionality, determined by their loss of degranulating capacity. Here we provide crucial information on the presence of degranulated mast cells (MCs)...
6.
Gaikwad A, Eapen M, Dey S, Bhattarai P, Shahzad A, Chia C, et al.
J Clin Med
. 2024 Feb;
13(4).
PMID: 38398472
We have previously reported that endothelial-to-mesenchymal transition (EndMT) is an active process in patients with idiopathic pulmonary fibrosis (IPF) contributing to arterial remodelling. Here, we aim to quantify drivers of...
7.
Bhattarai P, Lu W, Hardikar A, Dey S, Gaikwad A, Shahzad A, et al.
ERJ Open Res
. 2024 Feb;
10(1).
PMID: 38348240
Background: We have previously reported pulmonary arterial remodelling in smokers and patients with early COPD, which can be attributed to endothelial to mesenchymal transition (EndMT). In this study, we aimed...
8.
Malcom D, Park S, Lebovitz L, Attarabeen O, Castleberry A, Dey S, et al.
Am J Pharm Educ
. 2024 Feb;
88(3):100664.
PMID: 38311215
Objective: To assess pharmacy faculty members' perceptions of conditions associated with workload equity and factors that can improve workload equity. Methods: A 26-item survey instrument was developed and distributed via...
9.
Dey S, Lu W, Haug G, Chia C, Larby J, Weber H, et al.
Respir Res
. 2023 Sep;
24(1):221.
PMID: 37700291
Background: Although asthma and chronic obstructive pulmonary disease (COPD) are two distinct chronic airway inflammatory diseases, they often co-exist in a patient and the condition is referred to as asthma-COPD...
10.
Kumar H, Gupta N, Jain R, Madhunapantula S, Babu S, Dey S, et al.
Int J Pharm
. 2023 Jul;
643:123226.
PMID: 37451328
Salinomycin (Sal) is a potent veterinary antibiotic known to offer significant toxicity to the variety of neoplastic cells. Its therapeutic utility is limited due to its higher lipophilicity (logP 7.5)...